Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Entospletinib in combination with obinutuzumab in R/R CLL

Adam Kittai • 21 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Entospletinib Obinutuzumab

Adam Kittai, MD, Ohio State University, Columbus, OH, gave an overview of the phase I/II study of entospletinib in combination with obinutuzumab in patients with R/R chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Adam Kittai

1:42
What's on the horizon for patients with Richter's transformation?
Adam Kittai • 10 Dec 2023
2:49
Management of RT patients previously exposed to multiple lines of therapy
Adam Kittai • 10 Dec 2023
3:03
Outcomes of patients with Richter's transformation without prior chemoimmunotherapy for CLL/SLL
Adam Kittai • 10 Dec 2023
2:41
Anti-CD19 CAR-T for Richter’s transformation: an international multicenter retrospective study
Adam Kittai • 10 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals